Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

Key Points

• Ventyx Biosciences (VTYX) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.45) per share.
• The company's shares have decreased by 1.9% and are currently trading at $2.53, having a market cap of $180.03 million.
• Institutional investors hold 97.88% of Ventyx Biosciences' stock, with notable increases in holdings from firms like Acadian Asset Management and AQR Capital Management.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Ventyx Biosciences to post earnings of ($0.45) per share for the quarter.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. On average, analysts expect Ventyx Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Stock Down 1.9%

Shares of NASDAQ VTYX opened at $2.53 on Thursday. The company has a market capitalization of $180.03 million, a PE ratio of -1.45 and a beta of 0.97. Ventyx Biosciences has a twelve month low of $0.78 and a twelve month high of $3.39. The firm has a fifty day simple moving average of $2.52 and a 200 day simple moving average of $1.82.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC boosted its position in shares of Ventyx Biosciences by 443.8% during the 1st quarter. Acadian Asset Management LLC now owns 537,054 shares of the company's stock valued at $614,000 after purchasing an additional 438,286 shares in the last quarter. Jane Street Group LLC bought a new stake in Ventyx Biosciences in the first quarter worth approximately $56,000. Finally, AQR Capital Management LLC lifted its stake in Ventyx Biosciences by 925.6% in the first quarter. AQR Capital Management LLC now owns 880,222 shares of the company's stock valued at $1,012,000 after buying an additional 794,401 shares during the period. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.